Sopharma AD（SFA）株式概要Sopharma ADは、ヨーロッパ、ブルガリア、そして国際的に医薬品を製造、販売、輸出している。 詳細SFA ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績5/6財務の健全性4/6配当金3/6報酬株価収益率（ 14 x） BG市場（ 22.6 x）を下回っています。過去1年間で収益は75%増加しました リスク分析負債は営業キャッシュフローで十分にカバーされていない 1.58%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見るSFA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€1.841.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture05b2016201920222025202620282031Revenue лв4.5bEarnings лв228.6mAdvancedSet Fair ValueView all narrativesSopharma AD 競合他社Collegium PharmaceuticalSymbol: NasdaqGS:COLLMarket cap: US$1.1bTianjin Ringpu Bio-TechnologyLtdSymbol: SZSE:300119Market cap: CN¥7.2bSoho Global HealthSymbol: IDX:SOHOMarket cap: Rp19.6tCORONA RemediesSymbol: NSEI:CORONAMarket cap: ₹102.5b価格と性能株価の高値、安値、推移の概要Sopharma AD過去の株価現在の株価€1.8452週高値€2.0052週安値€1.09ベータ0.0731ヶ月の変化6.07%3ヶ月変化-0.81%1年変化61.65%3年間の変化82.53%5年間の変化204.16%IPOからの変化73.47%最新ニュースBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Alexandar Tchaouchev was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • May 13Here's Why Sopharma AD (BUL:SFA) Has Caught The Eye Of InvestorsThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...お知らせ • Dec 22+ 4 more updatesSopharma AD to Report Q1, 2026 Results on Jun 01, 2026Sopharma AD announced that they will report Q1, 2026 results on Jun 01, 2026Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Sep 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Sep 06There May Be Underlying Issues With The Quality Of Sopharma AD's (BUL:SFA) EarningsSopharma AD's ( BUL:SFA ) stock was strong after they recently reported robust earnings. We did some analysis and think...最新情報をもっと見るRecent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Alexandar Tchaouchev was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • May 13Here's Why Sopharma AD (BUL:SFA) Has Caught The Eye Of InvestorsThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...お知らせ • Dec 22+ 4 more updatesSopharma AD to Report Q1, 2026 Results on Jun 01, 2026Sopharma AD announced that they will report Q1, 2026 results on Jun 01, 2026Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Sep 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Sep 06There May Be Underlying Issues With The Quality Of Sopharma AD's (BUL:SFA) EarningsSopharma AD's ( BUL:SFA ) stock was strong after they recently reported robust earnings. We did some analysis and think...分析記事 • Jul 03Sopharma AD's (BUL:SFA) Dividend Will Be BGN0.08Sopharma AD's ( BUL:SFA ) investors are due to receive a payment of BGN0.08 per share on 25th of August. This means...分析記事 • Jul 01Is Sopharma AD (BUL:SFA) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Jun 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 26Sopharma AD, Annual General Meeting, Jun 27, 2025Sopharma AD, Annual General Meeting, Jun 27, 2025, at 11:00 FLE Standard Time. Location: sofia at 5 lachezar stanchev st, sofia BulgariaBoard Change • Apr 28Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Dec 21+ 6 more updatesSopharma AD to Report Fiscal Year 2025 Final Results on Apr 30, 2026Sopharma AD announced that they will report fiscal year 2025 final results on Apr 30, 2026お知らせ • Dec 20+ 1 more updateSopharma AD to Report Q1, 2025 Results on May 30, 2025Sopharma AD announced that they will report Q1, 2025 results on May 30, 2025Board Change • Dec 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Nov 01Upcoming dividend of лв0.075 per shareEligible shareholders must have bought the stock before 07 November 2024. Payment date: 23 December 2024. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 17%. Within top quartile of Bulgarian dividend payers (5.0%). Higher than average of industry peers (2.4%).分析記事 • Sep 07Sopharma AD's (BUL:SFA) Problems Go Beyond Weak ProfitThe subdued market reaction suggests that Sopharma AD's ( BUL:SFA ) recent earnings didn't contain any surprises. Our...Reported Earnings • Sep 01Second quarter 2024 earnings released: EPS: лв0.081 (vs лв0.26 in 2Q 2023)Second quarter 2024 results: EPS: лв0.081 (down from лв0.26 in 2Q 2023). Revenue: лв495.1m (up 9.3% from 2Q 2023). Net income: лв16.1m (down 48% from 2Q 2023). Profit margin: 3.3% (down from 6.9% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Jun 26Independent Director recently bought лв331k worth of stockOn the 24th of June, Alexandar Tchaoushev bought around 56k shares on-market at roughly лв5.96 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold лв958k more in shares than they bought in the last 12 months.Recent Insider Transactions • Jun 13Chairman recently bought лв124k worth of stockOn the 10th of June, Ognian Donev bought around 20k shares on-market at roughly лв6.20 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.4m.Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: лв0.23 (vs лв0.27 in 1Q 2023)First quarter 2024 results: EPS: лв0.23 (down from лв0.27 in 1Q 2023). Revenue: лв514.0m (up 9.5% from 1Q 2023). Net income: лв29.7m (down 7.9% from 1Q 2023). Profit margin: 5.8% (down from 6.9% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 20% per year.分析記事 • Jun 02Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt ResponsiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Buy Or Sell Opportunity • Mar 06Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to лв6.66. The fair value is estimated to be лв5.40, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.1% over the last 3 years. Earnings per share has grown by 25%. Revenue is forecast to grow by 5.3% in a year. Earnings are forecast to decline by 24% in the next year.Reported Earnings • Mar 03Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: EPS: лв0.73 (up from лв0.58 in FY 2022). Revenue: лв1.90b (up 13% from FY 2022). Net income: лв95.2m (up 34% from FY 2022). Profit margin: 5.0% (up from 4.3% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 24% per year.New Risk • Jan 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 12% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (0.9% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 225% Paying a dividend despite having no free cash flows. Earnings are forecast to decline by an average of 12% per year for the foreseeable future. Minor Risks Profit margins are more than 30% lower than last year (4.4% net profit margin). Shareholders have been diluted in the past year (31% increase in shares outstanding). Significant insider selling over the past 3 months (лв791k sold).Recent Insider Transactions • Dec 21Chairman recently sold лв527k worth of stockOn the 12th of December, Ognian Donev sold around 86k shares on-market at roughly лв6.10 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.7m.お知らせ • Dec 15+ 2 more updatesSopharma AD, Annual General Meeting, Jun 30, 2024Sopharma AD, Annual General Meeting, Jun 30, 2024.Recent Insider Transactions • Dec 14Chairman recently bought лв338k worth of stockOn the 8th of December, Ognian Donev bought around 55k shares on-market at roughly лв6.14 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.2m.New Risk • Dec 08New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 0.9% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (0.9% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 225% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). Shareholders have been diluted in the past year (31% increase in shares outstanding).Reported Earnings • Dec 01Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022)Third quarter 2023 results: EPS: лв0.12 (down from лв0.20 in 3Q 2022). Revenue: лв465.9m (up 12% from 3Q 2022). Net income: лв14.3m (down 42% from 3Q 2022). Profit margin: 3.1% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Nov 30Upcoming dividend of лв0.90 per share at 8.4% yieldEligible shareholders must have bought the stock before 07 December 2023. Payment date: 22 January 2024. Payout ratio is on the higher end at 80%, however this is supported by cash flows. Trailing yield: 8.4%. Within top quartile of Bulgarian dividend payers (7.4%). Higher than average of industry peers (2.6%).お知らせ • Nov 25Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024Sopharma AD at its EGM held on November 24, 2023, approved the proposal by the Board of Directors for the distribution of 6-month gross dividend amounting to BGN 0.90 (90 stotinki) per share. The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the EGM on which the financial statements of the Company for the first half of 2023 was approved and the decision for dividend was taken, namely December 8, 2023 (record date) ex-dividend date December 7, 2023. The starting date for dividend payment is January 22, 2024.New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bulgarian stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (212% cash payout ratio). Share price has been volatile over the past 3 months (4.8% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Significant insider selling over the past 3 months (лв1.6m sold).お知らせ • Oct 31Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023Sopharma AD announced that they will report Q3, 2023 results on Nov 29, 2023New Risk • Oct 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (212% cash payout ratio). Shareholders have been diluted in the past year (31% increase in shares outstanding). Significant insider selling over the past 3 months (лв1.6m sold).Recent Insider Transactions • Oct 01Chairman recently bought лв72k worth of stockOn the 28th of September, Ognian Donev bought around 10k shares on-market at roughly лв7.02 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth лв81k. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.5m.Valuation Update With 7 Day Price Move • Sep 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to лв7.18, the stock trades at a trailing P/E ratio of 9.5x. Average forward P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 160% over the past three years.お知らせ • Sep 21Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023Sopharma AD announced that they will report Q3, 2023 results on Oct 30, 2023Recent Insider Transactions • Sep 14Chairman recently bought лв81k worth of stockOn the 8th of September, Ognian Donev bought around 13k shares on-market at roughly лв6.20 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.5m.Recent Insider Transactions • Sep 07Chairman recently sold лв1.1m worth of stockOn the 1st of September, Ognian Donev sold around 778k shares on-market at roughly лв1.35 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.6m.お知らせ • Sep 06Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia.Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia on September 5, 2023. Sopharma AD (BUL:SFA) completed the acquisition of a 2.38% stake in Sopharma Buildings REIT-Sofia on September 5, 2023.Reported Earnings • Sep 01Second quarter 2023 earnings released: EPS: лв0.25 (vs лв0.19 in 2Q 2022)Second quarter 2023 results: EPS: лв0.25 (up from лв0.19 in 2Q 2022). Net income: лв31.2m (up 38% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Aug 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (100% cash payout ratio). Shareholders have been diluted in the past year (11% increase in shares outstanding). Significant insider selling over the past 3 months (лв156k sold).お知らせ • Jul 16Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o.Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o on July 14, 2023. Sopharma will initially acquire an interest of 25% in Pharmanova, then purchase another 50% ownership in a year's time, with the remaining 25% to be bought within two years. The transaction is subject to approval by the Serbian competition authority and is expected to complete within 2 years. As of FY 2022, Pharmanova generated net sales revenue of over €10.2 million.Recent Insider Transactions • Jul 06Chairman recently sold лв297k worth of stockOn the 30th of June, Ognian Donev sold around 28k shares on-market at roughly лв10.57 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ognian has been a net seller over the last 12 months, reducing personal holdings by лв297k.New Risk • Jun 15New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 11% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Upcoming Dividend • Jun 09Upcoming dividend of лв0.60 per shareEligible shareholders must have bought the stock before 15 June 2023. Payment date: 31 July 2023. The company last paid an ordinary dividend in March 2013. The average dividend yield among industry peers is 2.6%.お知らせ • Jun 03Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023Sopharma AD announced that, at the General Meeting of Shareholders of the company dated 02 June 2023 has taken the following dividend distribution decision for 2022: Gross dividend per share: BGN 0.60 - Dividend payout starting date: 31 July 2023. Dividend payout: Via the Central Depository and CB Eurobank Bulgaria AD /Postbank/The right to a dividend will be entitled to all shareholders registered with the central securities register on the 14th day following the GMS date, i.e. by 16 June 2023 (Record Date). The final date for transacting shares of this company on the Exchange, so the holder will be entitled to receive a dividend, will be 14 June 2023 (Ex-Dividend Date: 15 June 2023).Reported Earnings • May 31First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022)First quarter 2023 results: EPS: лв0.27 (up from лв0.17 in 1Q 2022). Revenue: лв469.9m (up 18% from 1Q 2022). Net income: лв32.3m (up 56% from 1Q 2022). Profit margin: 6.9% (up from 5.2% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 06Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: лв0.60 (down from лв0.71 in FY 2021). Revenue: лв1.67b (up 3.7% from FY 2021). Net income: лв72.6m (down 19% from FY 2021). Profit margin: 4.3% (down from 5.6% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Approved (during full year): 3 Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Dec 22Sopharma AD, Annual General Meeting, Jun 30, 2023Sopharma AD, Annual General Meeting, Jun 30, 2023.お知らせ • Dec 21+ 2 more updatesSopharma AD to Report Fiscal Year 2023 Results on Mar 29, 2024Sopharma AD announced that they will report fiscal year 2023 results on Mar 29, 2024Major Estimate Revision • Dec 09Consensus EPS estimates increase by 83%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from лв1.55b to лв1.65b. EPS estimate increased from лв0.29 to лв0.53 per share. Net income forecast to shrink 32% next year vs 13% growth forecast for Pharmaceuticals industry in Europe . Consensus price target up from лв4.17 to лв4.83. Share price was steady at лв4.50 over the past week.Price Target Changed • Dec 08Price target increased to лв4.83Up from лв3.98, the current price target is provided by 1 analyst. New target price is 7.3% above last closing price of лв4.50. Stock is up 1.4% over the past year. The company is forecast to post earnings per share of лв0.29 for next year compared to лв0.71 last year.Reported Earnings • Dec 01Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021)Third quarter 2022 results: EPS: лв0.20 (up from лв0.14 in 3Q 2021). Revenue: лв421.0m (flat on 3Q 2021). Net income: лв24.5m (up 34% from 3Q 2021). Profit margin: 5.8% (up from 4.3% in 3Q 2021). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 30Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021)Second quarter 2022 results: EPS: лв0.19 (up from лв0.12 in 2Q 2021). Revenue: лв409.1m (up 7.1% from 2Q 2021). Net income: лв22.7m (up 61% from 2Q 2021). Profit margin: 5.5% (up from 3.7% in 2Q 2021). Over the next year, revenue is expected to shrink by 4.0% compared to a 3.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 09Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million.Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million on June 8, 2022. As per the transaction, Sopharma AD made the offer to acquire remaining 14.6 million shares at BGN 8.2 per share.Reported Earnings • Jun 03First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021)First quarter 2022 results: EPS: лв0.17 (up from лв0.14 in 1Q 2021). Revenue: лв399.7m (up 4.8% from 1Q 2021). Net income: лв20.7m (up 14% from 1Q 2021). Profit margin: 5.2% (up from 4.8% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • May 03Sopharma AD, Annual General Meeting, Jun 03, 2022Sopharma AD, Annual General Meeting, Jun 03, 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 06Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022Sopharma AD announced that they will report fiscal year 2021 final results on Apr 29, 2022Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: лв0.73 (up from лв0.20 in FY 2020). Revenue: лв1.62b (up 12% from FY 2020). Net income: лв91.4m (up 266% from FY 2020). Profit margin: 5.7% (up from 1.7% in FY 2020). Revenue exceeded analyst estimates by 4.4%. Over the next year, revenue is forecast to stay flat compared to a 7.5% growth forecast for the pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 03Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022Sopharma AD announced that they will report fiscal year 2021 results on Mar 31, 2022お知らせ • Dec 30An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA).An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA) on December 29, 2021.Reported Earnings • Dec 02Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2021 results: EPS: лв0.14. Revenue: лв425.8m (up 24% from 3Q 2020). Net income: лв18.3m (up лв17.1m from 3Q 2020). Profit margin: 4.3% (up from 0.4% in 3Q 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 50%. Earnings per share (EPS) missed analyst estimates by 50%. Over the next year, revenue is forecast to stay flat compared to a 11% growth forecast for the industry in Europe. Over the last 3 years on average, earnings per share has increased by 7% per year and the company’s share price has also increased by 7% per year.Reported Earnings • Sep 03Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: лв384.4m (up 22% from 2Q 2020). Net income: лв14.1m (up 43% from 2Q 2020). Profit margin: 3.7% (up from 3.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 03Chairman recently bought лв79k worth of stockOn the 1st of September, Ognian Donev bought around 52k shares on-market at roughly лв1.52 per share. This was the largest purchase by an insider in the last 3 months. This was Ognian's only on-market trade for the last 12 months.Price Target Changed • Jul 26Price target decreased to лв3.48Down from лв3.98, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of лв3.48. Stock is up 18% over the past year.Price Target Changed • Jul 19Price target decreased to лв3.48Down from лв3.98, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of лв3.44. Stock is up 15% over the past year.Reported Earnings • Jun 02First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: лв382.8m (up 4.1% from 1Q 2020). Net income: лв18.1m (up 68% from 1Q 2020). Profit margin: 4.7% (up from 2.9% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.分析記事 • Apr 09Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Mar 05Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: лв1.45b (up 12% from FY 2019). Net income: лв25.0m (down 71% from FY 2019). Profit margin: 1.7% (down from 6.8% in FY 2019). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 21New 90-day high: лв3.50The company is up 14% from its price of лв3.08 on 20 November 2020. The Bulgarian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.分析記事 • Feb 20Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth WatchingSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...分析記事 • Feb 05How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?Every investor in Sopharma AD ( BUL:3JR ) should be aware of the most powerful shareholder groups. Insiders often own a...分析記事 • Jan 22Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...Is New 90 Day High Low • Jan 18New 90-day high: лв3.26The company is up 5.0% from its price of лв3.10 on 20 October 2020. The Bulgarian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is лв5.09 per share.お知らせ • Jan 10Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ.Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ on December 28, 2020. As a result of the transaction, Sopharma AD now owns 100% stake in SIA BRIZ. Sopharma AD (BUL:3JR) completed the acquisition of an unknown minority stake in SIA BRIZ on December 28, 2020.分析記事 • Jan 06Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...お知らせ • Dec 30An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR).An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR) on December 29, 2020. An unknown buyer completed the acquisition of majority stake of Aromania OOD from Sopharma AD (BUL:3JR) on December 29, 2020.分析記事 • Dec 22Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three YearsMany investors define successful investing as beating the market average over the long term. But the risk of stock...Is New 90 Day High Low • Dec 14New 90-day high: лв3.18The company is up 1.0% from its price of лв3.14 on 15 September 2020. The Bulgarian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is лв5.14 per share.分析記事 • Dec 07Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?Today we'll take a closer look at Sopharma AD ( BUL:3JR ) from a dividend investor's perspective. Owning a strong...分析記事 • Nov 19Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?How far off is Sopharma AD (BUL:3JR) from its intrinsic value? Using the most recent financial data, we'll take a look...Is New 90 Day High Low • Oct 26New 90-day high: лв3.16The company is up 7.0% from its price of лв2.96 on 28 July 2020. The Bulgarian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is лв4.16 per share.株主還元SFABG PharmaceuticalsBG 市場7D-0.3%0.9%0.2%1Y61.6%12.4%15.4%株主還元を見る業界別リターン: SFA過去 1 年間で12.4 % の収益を上げたBG Pharmaceuticals業界を上回りました。リターン対市場: SFA過去 1 年間で15.4 % の収益を上げたBG市場を上回りました。価格変動Is SFA's price volatile compared to industry and market?SFA volatilitySFA Average Weekly Movement2.7%Pharmaceuticals Industry Average Movement5.8%Market Average Movement5.9%10% most volatile stocks in BG Market9.3%10% least volatile stocks in BG Market2.9%安定した株価: SFA 、 BG市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: SFAの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19335,932Ognian Donevwww.sopharmagroup.comSopharma AD社は、ヨーロッパ、ブルガリア、および国際的に医薬品の製造、販売、輸出を行っている。肝疾患治療薬Carsil、鎮痛薬Tempalgin、鎮痛薬Analgin、禁煙補助薬Tabex、男性生殖器官刺激薬Tribestan、咳止め薬Broncholytin、末梢神経系治療薬Nivalin、重篤なアレルギーや生命を脅かす疾患治療薬Methylprednisolon、ビタミンC、ストレス軽減薬Valeriana、ガーゼ、湿布、ドレッシングなどの医療用具を提供している。同社はまた、食品サプリメント、絆創膏、包帯、ハーブ化粧品、衛生衛生製品などの医薬品・化粧品、血液透析用濃縮液、医療用医薬品、一般用医薬品、動物用医薬品も提供している。さらに、医薬品、医療用品、衛生材料、ビタミン剤、食品サプリメント、化粧品の販売、受託製造サービス、包装サービス、製品開発サービスも提供している。さらに、医薬品の売買、放射性物質や医療用原子力機器、家電製品、電気機器の売買、輸送、梱包、ハーブや薬草の購入、栽培、生産、売買、世論調査サービスの提供なども行っている。さらに、医薬品と医療機器のオフラインおよびオンライン小売、フランチャイズ、ノウハウ、不動産の賃貸、貿易、コンサルティング、その他の活動も行っている。ソファーマAD社は1933年に設立され、ブルガリアのソフィアに本社を置いている。もっと見るSopharma AD 基礎のまとめSopharma AD の収益と売上を時価総額と比較するとどうか。SFA 基礎統計学時価総額€964.35m収益（TTM）€68.97m売上高(TTM)€1.36b14.0xPER（株価収益率0.7xP/SレシオSFA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SFA 損益計算書（TTM）収益лв2.63b売上原価лв2.01b売上総利益лв625.13mその他の費用лв491.61m収益лв133.52m直近の収益報告Dec 31, 2025次回決算日Jun 01, 2026一株当たり利益（EPS）0.25グロス・マージン23.75%純利益率5.07%有利子負債／自己資本比率50.1%SFA の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.6%現在の配当利回り26%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 15:14終値2026/05/27 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sopharma AD 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Alexandar Tchaouchev was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • May 13Here's Why Sopharma AD (BUL:SFA) Has Caught The Eye Of InvestorsThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
お知らせ • Dec 22+ 4 more updatesSopharma AD to Report Q1, 2026 Results on Jun 01, 2026Sopharma AD announced that they will report Q1, 2026 results on Jun 01, 2026
Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Sep 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Sep 06There May Be Underlying Issues With The Quality Of Sopharma AD's (BUL:SFA) EarningsSopharma AD's ( BUL:SFA ) stock was strong after they recently reported robust earnings. We did some analysis and think...
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Alexandar Tchaouchev was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • May 13Here's Why Sopharma AD (BUL:SFA) Has Caught The Eye Of InvestorsThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
お知らせ • Dec 22+ 4 more updatesSopharma AD to Report Q1, 2026 Results on Jun 01, 2026Sopharma AD announced that they will report Q1, 2026 results on Jun 01, 2026
Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Sep 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Sep 06There May Be Underlying Issues With The Quality Of Sopharma AD's (BUL:SFA) EarningsSopharma AD's ( BUL:SFA ) stock was strong after they recently reported robust earnings. We did some analysis and think...
分析記事 • Jul 03Sopharma AD's (BUL:SFA) Dividend Will Be BGN0.08Sopharma AD's ( BUL:SFA ) investors are due to receive a payment of BGN0.08 per share on 25th of August. This means...
分析記事 • Jul 01Is Sopharma AD (BUL:SFA) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Jun 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 26Sopharma AD, Annual General Meeting, Jun 27, 2025Sopharma AD, Annual General Meeting, Jun 27, 2025, at 11:00 FLE Standard Time. Location: sofia at 5 lachezar stanchev st, sofia Bulgaria
Board Change • Apr 28Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Dec 21+ 6 more updatesSopharma AD to Report Fiscal Year 2025 Final Results on Apr 30, 2026Sopharma AD announced that they will report fiscal year 2025 final results on Apr 30, 2026
お知らせ • Dec 20+ 1 more updateSopharma AD to Report Q1, 2025 Results on May 30, 2025Sopharma AD announced that they will report Q1, 2025 results on May 30, 2025
Board Change • Dec 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Nov 01Upcoming dividend of лв0.075 per shareEligible shareholders must have bought the stock before 07 November 2024. Payment date: 23 December 2024. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 17%. Within top quartile of Bulgarian dividend payers (5.0%). Higher than average of industry peers (2.4%).
分析記事 • Sep 07Sopharma AD's (BUL:SFA) Problems Go Beyond Weak ProfitThe subdued market reaction suggests that Sopharma AD's ( BUL:SFA ) recent earnings didn't contain any surprises. Our...
Reported Earnings • Sep 01Second quarter 2024 earnings released: EPS: лв0.081 (vs лв0.26 in 2Q 2023)Second quarter 2024 results: EPS: лв0.081 (down from лв0.26 in 2Q 2023). Revenue: лв495.1m (up 9.3% from 2Q 2023). Net income: лв16.1m (down 48% from 2Q 2023). Profit margin: 3.3% (down from 6.9% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Jun 26Independent Director recently bought лв331k worth of stockOn the 24th of June, Alexandar Tchaoushev bought around 56k shares on-market at roughly лв5.96 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold лв958k more in shares than they bought in the last 12 months.
Recent Insider Transactions • Jun 13Chairman recently bought лв124k worth of stockOn the 10th of June, Ognian Donev bought around 20k shares on-market at roughly лв6.20 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.4m.
Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: лв0.23 (vs лв0.27 in 1Q 2023)First quarter 2024 results: EPS: лв0.23 (down from лв0.27 in 1Q 2023). Revenue: лв514.0m (up 9.5% from 1Q 2023). Net income: лв29.7m (down 7.9% from 1Q 2023). Profit margin: 5.8% (down from 6.9% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 20% per year.
分析記事 • Jun 02Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt ResponsiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Buy Or Sell Opportunity • Mar 06Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to лв6.66. The fair value is estimated to be лв5.40, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.1% over the last 3 years. Earnings per share has grown by 25%. Revenue is forecast to grow by 5.3% in a year. Earnings are forecast to decline by 24% in the next year.
Reported Earnings • Mar 03Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: EPS: лв0.73 (up from лв0.58 in FY 2022). Revenue: лв1.90b (up 13% from FY 2022). Net income: лв95.2m (up 34% from FY 2022). Profit margin: 5.0% (up from 4.3% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 24% per year.
New Risk • Jan 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 12% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (0.9% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 225% Paying a dividend despite having no free cash flows. Earnings are forecast to decline by an average of 12% per year for the foreseeable future. Minor Risks Profit margins are more than 30% lower than last year (4.4% net profit margin). Shareholders have been diluted in the past year (31% increase in shares outstanding). Significant insider selling over the past 3 months (лв791k sold).
Recent Insider Transactions • Dec 21Chairman recently sold лв527k worth of stockOn the 12th of December, Ognian Donev sold around 86k shares on-market at roughly лв6.10 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.7m.
お知らせ • Dec 15+ 2 more updatesSopharma AD, Annual General Meeting, Jun 30, 2024Sopharma AD, Annual General Meeting, Jun 30, 2024.
Recent Insider Transactions • Dec 14Chairman recently bought лв338k worth of stockOn the 8th of December, Ognian Donev bought around 55k shares on-market at roughly лв6.14 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.2m.
New Risk • Dec 08New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 0.9% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (0.9% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 225% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). Shareholders have been diluted in the past year (31% increase in shares outstanding).
Reported Earnings • Dec 01Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022)Third quarter 2023 results: EPS: лв0.12 (down from лв0.20 in 3Q 2022). Revenue: лв465.9m (up 12% from 3Q 2022). Net income: лв14.3m (down 42% from 3Q 2022). Profit margin: 3.1% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Nov 30Upcoming dividend of лв0.90 per share at 8.4% yieldEligible shareholders must have bought the stock before 07 December 2023. Payment date: 22 January 2024. Payout ratio is on the higher end at 80%, however this is supported by cash flows. Trailing yield: 8.4%. Within top quartile of Bulgarian dividend payers (7.4%). Higher than average of industry peers (2.6%).
お知らせ • Nov 25Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024Sopharma AD at its EGM held on November 24, 2023, approved the proposal by the Board of Directors for the distribution of 6-month gross dividend amounting to BGN 0.90 (90 stotinki) per share. The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the EGM on which the financial statements of the Company for the first half of 2023 was approved and the decision for dividend was taken, namely December 8, 2023 (record date) ex-dividend date December 7, 2023. The starting date for dividend payment is January 22, 2024.
New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bulgarian stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (212% cash payout ratio). Share price has been volatile over the past 3 months (4.8% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Significant insider selling over the past 3 months (лв1.6m sold).
お知らせ • Oct 31Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023Sopharma AD announced that they will report Q3, 2023 results on Nov 29, 2023
New Risk • Oct 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (212% cash payout ratio). Shareholders have been diluted in the past year (31% increase in shares outstanding). Significant insider selling over the past 3 months (лв1.6m sold).
Recent Insider Transactions • Oct 01Chairman recently bought лв72k worth of stockOn the 28th of September, Ognian Donev bought around 10k shares on-market at roughly лв7.02 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth лв81k. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.5m.
Valuation Update With 7 Day Price Move • Sep 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to лв7.18, the stock trades at a trailing P/E ratio of 9.5x. Average forward P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 160% over the past three years.
お知らせ • Sep 21Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023Sopharma AD announced that they will report Q3, 2023 results on Oct 30, 2023
Recent Insider Transactions • Sep 14Chairman recently bought лв81k worth of stockOn the 8th of September, Ognian Donev bought around 13k shares on-market at roughly лв6.20 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.5m.
Recent Insider Transactions • Sep 07Chairman recently sold лв1.1m worth of stockOn the 1st of September, Ognian Donev sold around 778k shares on-market at roughly лв1.35 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.6m.
お知らせ • Sep 06Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia.Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia on September 5, 2023. Sopharma AD (BUL:SFA) completed the acquisition of a 2.38% stake in Sopharma Buildings REIT-Sofia on September 5, 2023.
Reported Earnings • Sep 01Second quarter 2023 earnings released: EPS: лв0.25 (vs лв0.19 in 2Q 2022)Second quarter 2023 results: EPS: лв0.25 (up from лв0.19 in 2Q 2022). Net income: лв31.2m (up 38% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Aug 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (100% cash payout ratio). Shareholders have been diluted in the past year (11% increase in shares outstanding). Significant insider selling over the past 3 months (лв156k sold).
お知らせ • Jul 16Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o.Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o on July 14, 2023. Sopharma will initially acquire an interest of 25% in Pharmanova, then purchase another 50% ownership in a year's time, with the remaining 25% to be bought within two years. The transaction is subject to approval by the Serbian competition authority and is expected to complete within 2 years. As of FY 2022, Pharmanova generated net sales revenue of over €10.2 million.
Recent Insider Transactions • Jul 06Chairman recently sold лв297k worth of stockOn the 30th of June, Ognian Donev sold around 28k shares on-market at roughly лв10.57 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ognian has been a net seller over the last 12 months, reducing personal holdings by лв297k.
New Risk • Jun 15New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 11% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Upcoming Dividend • Jun 09Upcoming dividend of лв0.60 per shareEligible shareholders must have bought the stock before 15 June 2023. Payment date: 31 July 2023. The company last paid an ordinary dividend in March 2013. The average dividend yield among industry peers is 2.6%.
お知らせ • Jun 03Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023Sopharma AD announced that, at the General Meeting of Shareholders of the company dated 02 June 2023 has taken the following dividend distribution decision for 2022: Gross dividend per share: BGN 0.60 - Dividend payout starting date: 31 July 2023. Dividend payout: Via the Central Depository and CB Eurobank Bulgaria AD /Postbank/The right to a dividend will be entitled to all shareholders registered with the central securities register on the 14th day following the GMS date, i.e. by 16 June 2023 (Record Date). The final date for transacting shares of this company on the Exchange, so the holder will be entitled to receive a dividend, will be 14 June 2023 (Ex-Dividend Date: 15 June 2023).
Reported Earnings • May 31First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022)First quarter 2023 results: EPS: лв0.27 (up from лв0.17 in 1Q 2022). Revenue: лв469.9m (up 18% from 1Q 2022). Net income: лв32.3m (up 56% from 1Q 2022). Profit margin: 6.9% (up from 5.2% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 06Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: лв0.60 (down from лв0.71 in FY 2021). Revenue: лв1.67b (up 3.7% from FY 2021). Net income: лв72.6m (down 19% from FY 2021). Profit margin: 4.3% (down from 5.6% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Approved (during full year): 3 Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Dec 22Sopharma AD, Annual General Meeting, Jun 30, 2023Sopharma AD, Annual General Meeting, Jun 30, 2023.
お知らせ • Dec 21+ 2 more updatesSopharma AD to Report Fiscal Year 2023 Results on Mar 29, 2024Sopharma AD announced that they will report fiscal year 2023 results on Mar 29, 2024
Major Estimate Revision • Dec 09Consensus EPS estimates increase by 83%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from лв1.55b to лв1.65b. EPS estimate increased from лв0.29 to лв0.53 per share. Net income forecast to shrink 32% next year vs 13% growth forecast for Pharmaceuticals industry in Europe . Consensus price target up from лв4.17 to лв4.83. Share price was steady at лв4.50 over the past week.
Price Target Changed • Dec 08Price target increased to лв4.83Up from лв3.98, the current price target is provided by 1 analyst. New target price is 7.3% above last closing price of лв4.50. Stock is up 1.4% over the past year. The company is forecast to post earnings per share of лв0.29 for next year compared to лв0.71 last year.
Reported Earnings • Dec 01Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021)Third quarter 2022 results: EPS: лв0.20 (up from лв0.14 in 3Q 2021). Revenue: лв421.0m (flat on 3Q 2021). Net income: лв24.5m (up 34% from 3Q 2021). Profit margin: 5.8% (up from 4.3% in 3Q 2021). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 30Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021)Second quarter 2022 results: EPS: лв0.19 (up from лв0.12 in 2Q 2021). Revenue: лв409.1m (up 7.1% from 2Q 2021). Net income: лв22.7m (up 61% from 2Q 2021). Profit margin: 5.5% (up from 3.7% in 2Q 2021). Over the next year, revenue is expected to shrink by 4.0% compared to a 3.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 09Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million.Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million on June 8, 2022. As per the transaction, Sopharma AD made the offer to acquire remaining 14.6 million shares at BGN 8.2 per share.
Reported Earnings • Jun 03First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021)First quarter 2022 results: EPS: лв0.17 (up from лв0.14 in 1Q 2021). Revenue: лв399.7m (up 4.8% from 1Q 2021). Net income: лв20.7m (up 14% from 1Q 2021). Profit margin: 5.2% (up from 4.8% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • May 03Sopharma AD, Annual General Meeting, Jun 03, 2022Sopharma AD, Annual General Meeting, Jun 03, 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 06Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022Sopharma AD announced that they will report fiscal year 2021 final results on Apr 29, 2022
Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: лв0.73 (up from лв0.20 in FY 2020). Revenue: лв1.62b (up 12% from FY 2020). Net income: лв91.4m (up 266% from FY 2020). Profit margin: 5.7% (up from 1.7% in FY 2020). Revenue exceeded analyst estimates by 4.4%. Over the next year, revenue is forecast to stay flat compared to a 7.5% growth forecast for the pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 03Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022Sopharma AD announced that they will report fiscal year 2021 results on Mar 31, 2022
お知らせ • Dec 30An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA).An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA) on December 29, 2021.
Reported Earnings • Dec 02Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2021 results: EPS: лв0.14. Revenue: лв425.8m (up 24% from 3Q 2020). Net income: лв18.3m (up лв17.1m from 3Q 2020). Profit margin: 4.3% (up from 0.4% in 3Q 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 50%. Earnings per share (EPS) missed analyst estimates by 50%. Over the next year, revenue is forecast to stay flat compared to a 11% growth forecast for the industry in Europe. Over the last 3 years on average, earnings per share has increased by 7% per year and the company’s share price has also increased by 7% per year.
Reported Earnings • Sep 03Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: лв384.4m (up 22% from 2Q 2020). Net income: лв14.1m (up 43% from 2Q 2020). Profit margin: 3.7% (up from 3.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 03Chairman recently bought лв79k worth of stockOn the 1st of September, Ognian Donev bought around 52k shares on-market at roughly лв1.52 per share. This was the largest purchase by an insider in the last 3 months. This was Ognian's only on-market trade for the last 12 months.
Price Target Changed • Jul 26Price target decreased to лв3.48Down from лв3.98, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of лв3.48. Stock is up 18% over the past year.
Price Target Changed • Jul 19Price target decreased to лв3.48Down from лв3.98, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of лв3.44. Stock is up 15% over the past year.
Reported Earnings • Jun 02First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: лв382.8m (up 4.1% from 1Q 2020). Net income: лв18.1m (up 68% from 1Q 2020). Profit margin: 4.7% (up from 2.9% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
分析記事 • Apr 09Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Mar 05Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: лв1.45b (up 12% from FY 2019). Net income: лв25.0m (down 71% from FY 2019). Profit margin: 1.7% (down from 6.8% in FY 2019). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 21New 90-day high: лв3.50The company is up 14% from its price of лв3.08 on 20 November 2020. The Bulgarian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
分析記事 • Feb 20Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth WatchingSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
分析記事 • Feb 05How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?Every investor in Sopharma AD ( BUL:3JR ) should be aware of the most powerful shareholder groups. Insiders often own a...
分析記事 • Jan 22Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
Is New 90 Day High Low • Jan 18New 90-day high: лв3.26The company is up 5.0% from its price of лв3.10 on 20 October 2020. The Bulgarian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is лв5.09 per share.
お知らせ • Jan 10Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ.Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ on December 28, 2020. As a result of the transaction, Sopharma AD now owns 100% stake in SIA BRIZ. Sopharma AD (BUL:3JR) completed the acquisition of an unknown minority stake in SIA BRIZ on December 28, 2020.
分析記事 • Jan 06Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
お知らせ • Dec 30An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR).An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR) on December 29, 2020. An unknown buyer completed the acquisition of majority stake of Aromania OOD from Sopharma AD (BUL:3JR) on December 29, 2020.
分析記事 • Dec 22Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three YearsMany investors define successful investing as beating the market average over the long term. But the risk of stock...
Is New 90 Day High Low • Dec 14New 90-day high: лв3.18The company is up 1.0% from its price of лв3.14 on 15 September 2020. The Bulgarian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is лв5.14 per share.
分析記事 • Dec 07Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?Today we'll take a closer look at Sopharma AD ( BUL:3JR ) from a dividend investor's perspective. Owning a strong...
分析記事 • Nov 19Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?How far off is Sopharma AD (BUL:3JR) from its intrinsic value? Using the most recent financial data, we'll take a look...
Is New 90 Day High Low • Oct 26New 90-day high: лв3.16The company is up 7.0% from its price of лв2.96 on 28 July 2020. The Bulgarian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is лв4.16 per share.
